Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2024-02-20 00:00:00 ET · period of report 2024-02-15 · accession 0000950170-24-017494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-20 | 2024-02-15 | SYRE | Turtle Cameron | CEO, Dir | A - Grant | $9.82 | +400 | 746.9K | +0.1% | +$3,928 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | A | A | 400 | $9.82 | 746,907 | D | — | — | (F2) Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. |